SanBio was established in the world's mecca for biopharmaceutical development, the San Francisco Bay Area (Silicon Valley), in 2001. Since its establishment, SanBio has worked to develop new neuro-regenerative cell medicines to serve the world market.
In 2014, the Company’s regenerative cell medicine, SB623, yielded promising safety and efficacy in patients suffering from chronic dysfunction resulting from ischemic stroke in a Phase 1/2a study conducted under United States Food and Drug Administration (FDA) regulations.
Moreover, in Japan during 2014, the revised Pharmaceutical Affairs Law and the new Regenerative Medicine Law were passed, quickly creating the world's most favorable regulatory regime for accelerating approval of regenerative therapeutic products.
SanBio’s goal is to become a global leader in the field of next-generation regenerative cell medicine. In order to achieve this goal, SanBio went public on the Mothers section of the Tokyo Stock Exchange and began full-scale product development in Japan.
Based upon our strength of our research and development in the U.S. and the fast-track approval system in Japan, we expect to become a global leader in regenerative cell medicines and generate robust growth as a company. We thank our investors and partners for their continued support and encouragement.
We look forward to your continued guidance and encouragement.
Keita Mori, CEO